HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01438060

Aripiprazole or Placebo for Psychosis in Alzheimer’s Disease

About this titleRead the official source — NCT01438060
Medication studyAges 55–95Schizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 55 years to 95 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2000
Recruitment status
Completed
Enrollment listed in the registry
232
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 55 Years to 95 Years
Official registry ID
NCT01438060
Official title
Show the full official title

A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole (BMS-337039) and Placebo.

Who was this study for?

Listed age limits: 55 years to 95 years.

Want to explore more studies?

Explore studies